IMMUNOGENICITY AND SAFETY OF HEPLISAV-B (R) (HepB-CpG) COMPARED WITH ENGERIX-B (R) (HepB-ENG) IN PATIENTS WITH CHRONIC LIVER DISEASE IN THREE PIVOTAL, PHASE 3 TRIALSJosh Levitsky,John Youhanna,Kelvin Mckoy,Robert JanssenHEPATOLOGY（2021）引用 1|浏览3暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
